Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Asalyxa Bio, a US-based developer of immune cell-targeted therapeutics spun out of University of Michigan, has completed a $2m seed round co-led by Research Bridge Partners and ID Ventures, with participation from the Biosciences Research and Commercialization Center at Western Michigan University, Michigan Rise Pre-Seed Fund III, Ann Arbor Spark, Woodward Angels and undisclosed investors.…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.